- Home
- GALT vs IVVD Comparison
GALT vs IVVD Comparison
Compare GALT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- IVVD
- Stock Information
- Founded
- GALT 2000
- IVVD 2020
- Country
- GALT United States
- IVVD United States
- Employees
- GALT N/A
- IVVD N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- IVVD Health Care
- Exchange
- GALT Nasdaq
- IVVD Nasdaq
- Market Cap
- GALT 83.5M
- IVVD 69.0M
- IPO Year
- GALT N/A
- IVVD 2021
- Fundamental
- Price
- GALT $2.60
- IVVD $0.75
- Analyst Decision
- GALT Buy
- IVVD Strong Buy
- Analyst Count
- GALT 2
- IVVD 3
- Target Price
- GALT $6.00
- IVVD $5.85
- AVG Volume (30 Days)
- GALT 1.2M
- IVVD 1.8M
- Earning Date
- GALT 08-12-2025
- IVVD 08-13-2025
- Dividend Yield
- GALT N/A
- IVVD N/A
- EPS Growth
- GALT N/A
- IVVD N/A
- EPS
- GALT N/A
- IVVD N/A
- Revenue
- GALT N/A
- IVVD $36,688,000.00
- Revenue This Year
- GALT N/A
- IVVD $446.60
- Revenue Next Year
- GALT N/A
- IVVD $112.63
- P/E Ratio
- GALT N/A
- IVVD N/A
- Revenue Growth
- GALT N/A
- IVVD N/A
- 52 Week Low
- GALT $0.73
- IVVD $0.35
- 52 Week High
- GALT $3.90
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- GALT 70.66
- IVVD 43.27
- Support Level
- GALT $1.28
- IVVD $0.70
- Resistance Level
- GALT $1.36
- IVVD $1.03
- Average True Range (ATR)
- GALT 0.33
- IVVD 0.07
- MACD
- GALT 0.18
- IVVD -0.03
- Stochastic Oscillator
- GALT 52.40
- IVVD 12.75
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.